RORA and colorectal carcinoma: It was shown that products of a novel CYP11A1-dependent pathway of vitamin D metabolism, such as 20(OH) D3 (which the present study shows to inhibit CRC proliferation) and 20,23(OH)2D3, can act as antagonists or inverse agonists on RORα and RORγ (27).